<DOC>
	<DOCNO>NCT03001115</DOCNO>
	<brief_summary>The objective study evaluate safety profile Adalimumab Hidradenitis Suppurativa ( HS ) participant normal medical practice .</brief_summary>
	<brief_title>Post-Marketing Surveillance Adalimumab Korean Hidradenitis Suppurativa Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant eligible treat adalimumab HS accordance approve Korean label Participant must provide write authorization form use personal health data prior participate study . Participant contraindication adalimumab list approved Korean label . Participant participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Korean participant</keyword>
	<keyword>Hidradenitis Suppurativa</keyword>
	<keyword>Safety</keyword>
	<keyword>Adalimumab</keyword>
</DOC>